display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - L1 - HER2 negative
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC CheckMate 649

Study type: